Cargando…

Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience

Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Califano, Daniela, Russo, Daniela, Scognamiglio, Giosuè, Losito, Nunzia Simona, Spina, Anna, Bello, Anna Maria, Capiluongo, Anna, Galdiero, Francesca, De Cecio, Rossella, Bevilacqua, Simona, Gargiulo, Piera, Marchesi, Edoardo, Canevari, Silvana, Perrone, Francesco, Daniele, Gennaro, De Cecco, Loris, Mezzanzanica, Delia, Pignata, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226822/ https://www.ncbi.nlm.nih.gov/pubmed/32272732 http://dx.doi.org/10.3390/cells9040903

Ejemplares similares

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022)

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
por: Califano, Daniela, et al.
Publicado: (2021)

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab
por: Fabbi, Marina, et al.
Publicado: (2022)

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
por: Perrone, Francesco, et al.
Publicado: (2016)

Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial
por: Forlani, Luca, et al.
Publicado: (2023)

Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer
por: Galdiero, Francesca, et al.
Publicado: (2015)

Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets
por: De Cecco, Loris, et al.
Publicado: (2021)

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
por: Bagnoli, Marina, et al.
Publicado: (2011)

Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients
por: Bagnoli, Marina, et al.
Publicado: (2011)

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
por: Capoluongo, E.D., et al.
Publicado: (2022)

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016)

A miRNA signature assessing ovarian cancer prognosis
por: Bagnoli, Marina, et al.
Publicado: (2016)

Choline Metabolism Alteration: A Focus on Ovarian Cancer
por: Bagnoli, Marina, et al.
Publicado: (2016)

Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer
por: Cioffi, Michele, et al.
Publicado: (2015)

Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion
por: Minopoli, Michele, et al.
Publicado: (2019)

Duodenal gangliocytic paraganglioma, a rare entity among GEP-NET: a case report with immunohistochemical and molecular study
por: Tatangelo, Fabiana, et al.
Publicado: (2014)

Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth
por: Rea, Katia, et al.
Publicado: (2018)

Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
por: Barcellini, Amelia, et al.
Publicado: (2022)

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer
por: Canese, Rossella, et al.
Publicado: (2016)

Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer
por: Granata, A, et al.
Publicado: (2014)

AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
por: Azzalini, Eros, et al.
Publicado: (2022)

Identification of BAG3 target proteins in anaplastic thyroid cancer cells by proteomic analysis
por: Galdiero, Francesca, et al.
Publicado: (2018)

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer
por: Pisano, Carmela, et al.
Publicado: (2013)

Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study
por: Dugo, Matteo, et al.
Publicado: (2019)

Ovarian cancer: a molecularly insidious disease
por: Mezzanzanica, Delia
Publicado: (2015)

Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells
por: Rizzo, Andrea, et al.
Publicado: (2021)

Massive edema of ovary with cytogenetic alteration of chromosome 12q13-15 in adolescent patient: a case report
por: De Cecio, Rossella, et al.
Publicado: (2013)

Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells
por: De Cecco, Loris, et al.
Publicado: (2015)

Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups
por: Greggi, Stefano, et al.
Publicado: (2022)

Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study
por: De Cecio, Rossella, et al.
Publicado: (2014)

Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma
por: Granata, Anna, et al.
Publicado: (2015)

Clinicopathological Impact of ABCC1/MRP1 and ABCC4/MRP4 in Epithelial Ovarian Carcinoma
por: Bagnoli, Marina, et al.
Publicado: (2013)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
por: Neve Polimeno, Maria, et al.
Publicado: (2015)

Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence
por: Bifulco, Katia, et al.
Publicado: (2014)

Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer
por: Passarelli, Anna, et al.
Publicado: (2022)

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study
por: Pignata, Sandro, et al.
Publicado: (2006)

Genetics and Molecular Basis of Congenital Heart Defects in Down Syndrome: Role of Extracellular Matrix Regulation
por: Mollo, Nunzia, et al.
Publicado: (2023)

Characterization of BRCA Deficiency in Ovarian Cancer
por: Barbero, Giovanna, et al.
Publicado: (2023)

Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
por: Roggiani, Francesca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qtffamu5pfjvr19evnbr7717v8